OOIR: Observatory of International Research

Papers

(The TQCC of Nephrology Dialysis Transplantation is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration	300
Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA	252
Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey	136
Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controls	110
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics	108
European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4–G5D	104
How should I manage immunosuppression in a kidney transplant patient with COVID-19? An ERA-EDTA DESCARTES expert opinion	92
High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients	83
Chronic kidney disease and acute kidney injury in the COVID-19 Spanish outbreak	81
Antibody response to mRNA SARS-CoV-2 vaccine among dialysis patients—a prospective cohort study	80
Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES)	76
Roxadustat for anemia in patients with end-stage renal disease incident to dialysis	68
Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS)	67
Kidney allograft recipients, immunosuppression, and coronavirus disease-2019: a report of consecutive cases from a New York City transplant center	66
Genetic testing in the diagnosis of chronic kidney disease: recommendations for clinical practice	65
Does dietary potassium intake associate with hyperkalemia in patients with chronic kidney disease?	64
COVID-19-related mortality in kidney transplant and haemodialysis patients: a comparative, prospective registry-based study	62
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease	60
Targeting acute kidney injury in COVID-19	59
Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial	57
Renal gluconeogenesis: an underestimated role of the kidney in systemic glucose metabolism	55
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in a haemodialysis cohort	53
An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disea	48
Acute kidney injury in patients hospitalized with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study	48
Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone	48

Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)	47
Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAP	45
The spectrum of kidney biopsies in hospitalized patients with COVID-19, acute kidney injury and/or proteinuria	44
At least 156 reasons to prioritize COVID-19 vaccination in patients receiving in-centre haemodialysis	44
Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort	42
Volume overload in hemodialysis: diagnosis, cardiovascular consequences, and management	42
The impact of chronic kidney disease Stages 3–5 on pregnancy outcomes	42
Meaning of empowerment in peritoneal dialysis: focus groups with patients and caregivers	42
Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results	41
Clinical utility of genetic testing in early-onset kidney disease: seven genes are the main players	41
Clinical and predictive value of simplified creatinine index used as muscle mass surrogate in end-stage kidney disease haemodialysis patients—results from the international MONitoring Dialysis Outcome	39
Nephrotic syndrome and vasculitis following SARS-CoV-2 vaccine: true association or circumstantial?	38
Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study	36
Acute kidney injury and urinary biomarkers in hospitalized patients with coronavirus disease-2019	36
Differential role of nicotinamide adenine dinucleotide deficiency in acute and chronic kidney disease	35
Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases	35
Performance of creatinine-based equations to estimate glomerular filtration rate in White and Black populations in Europe, Brazil and Africa	35
Prevalence and outcomes of hyponatremia and hypernatremia in patients hospitalized with COVID-19	35
Impact of longer term phosphorus control on cardiovascular mortality in hemodialysis patients using an area under the curve approach: results from the DOPPS	34
Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: the SENCOVAC study	34
Idiopathic retroperitoneal fibrosis: an update for nephrologists	33
PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab	33
Myostatin and muscle atrophy during chronic kidney disease	33
Free p-cresyl sulfate shows the highest association with cardiovascular outcome in chronic kidney disease	32
How to tackle health literacy problems in chronic kidney disease patients? A systematic review to identify promising intervention targets and strategies	32
Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results	31
Urine proteomics for prediction of disease progression in patients with IgA nephropathy	31
High levels of gut-homing immunoglobulin A+ B lymphocytes support the pathogenic role of intestinal mucosal hyperresponsiveness in immunoglobulin A nephropathy patients	30
Bone evaluation in paediatric chronic kidney disease: clinical practice points from the European Society for Paediatric Nephrology CKD-MBD and Dialysis working groups and CKD-MBD working group of the	30
Impact of first-wave COronaVIrus disease 2019 infection in patients on haemoDIALysis in Alsace: the observational COVIDIAL study	30
What should European nephrology do with the new CKD-EPI equation?	30
Independent effects of secondary hyperparathyroidism and hyperphosphataemia on chronic kidney disease progression and cardiovascular events: an analysis from the NEFRONA cohort	29
SGLT2 inhibition requires reconsideration of fundamental paradigms in chronic kidney disease, ‘diabetic nephropathy’, IgA nephropathy and podocytopathies with FSGS lesions	29
The RECOVAC IR study: the immune response and safety of the mRNA-1273 COVID-19 vaccine in patients with chronic kidney disease, on dialysis or living with a kidney transplant	29
Acute kidney injury in patients with COVID-19: an update on the pathophysiology	28
Novel insights into the disease transcriptome of human diabetic glomeruli and tubulointerstitium	28
Contribution of uremic dysbiosis to insulin resistance and sarcopenia	28
Health-related quality of life and symptoms of conservative care versus dialysis in patients with end-stage kidney disease: a systematic review	28
Metagenomic profiling of gut microbiome in early chronic kidney disease	28
Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors	28
Tissue sodium stores in peritoneal dialysis and hemodialysis patients determined by sodium-23 magnetic resonance imaging	27
Mapping health-related quality of life after kidney transplantation by group comparisons: a systematic review	27
Measured sodium excretion is associated with CKD progression: results from the KNOW-CKD study	27
Effects of calcitriol and paricalcitol on renal fibrosis in CKD	27
Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?	26
Management of obesity in kidney transplant candidates and recipients: A clinical practice guideline by the DESCARTES Working Group of ERA	26
Urine interleukin-9 and tumor necrosis factor-α for prognosis of human acute interstitial nephritis	26
Early versus late acute kidney injury among patients with COVID-19—a multicenter study from Wuhan, China	26
Renin–angiotensin system blocker discontinuation and adverse outcomes in chronic kidney disease	25
The cholinergic anti-inflammatory pathway in chronic kidney disease—review and vagus nerve stimulation clinical pilot study	25

Clinical characterization of primary hyperoxaluria type 3 in comparison with types 1 and 2	25
Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease	25
Effects of Oxalobacter formigenes in subjects with primary hyperoxaluria Type 1 and end-stage renal disease: a Phase II study	24
Genetics-first approach improves diagnostics of ESKD patients <50 years old	24
Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients	24
Cognitive disorders in patients with chronic kidney disease: specificities of clinical assessment	23
International prescribing patterns and polypharmacy in older people with advanced chronic kidney disease: results from the European Quality study	23
Kidney disease pathways, options and decisions: an environmental scan of international patient decision aids	23
Anticoagulation management in haemodialysis patients with atrial fibrillation: evidence and opinion	23
Hypoxia in chronic kidney disease: towards a paradigm shift?	23
Renal denervation in patients with versus without chronic kidney disease: results from the Global SYMPLICITY Registry with follow-up data of 3 years	23
Hypocalcemia and bone mineral changes in hemodialysis patients with low bone mass treated with denosumab: a 2-year observational study	22
Nutritional status, hyperkalaemia and attainment of energy/protein intake targets in haemodialysis patients following plant-based diets: a longitudinal cohort study	22
Effect of hemodiafiltration on measured physical activity: primary results of the HDFIT randomized controlled trial	22
Dietary plant and animal protein intake and decline in estimated glomerular filtration rate among elderly women: a 10-year longitudinal cohort study	22
The European Green Deal and nephrology: a call for action by the European Kidney Health Alliance	22
Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS	22
Bleeding risk of haemodialysis and peritoneal dialysis patients	22
Magnesium to prevent kidney disease–associated vascular calcification: crystal clear?	22
Kidney biopsy chronicity grading in antineutrophil cytoplasmic antibody-associated vasculitis	22
ERACODA: the European database collecting clinical information of patients on kidney replacement therapy with COVID-19	21
Persistence of antibody response to SARS-CoV-2 in a cohort of haemodialysis patients with COVID-19	21
Tubulointerstitial nephritis and uveitis syndrome: a systematic review	21
Endotrophin, a collagen type VI-derived matrikine, reflects the degree of renal fibrosis in patients with IgA nephropathy and in patients with ANCA-associated vasculitis	21
Removing race from the CKD-EPI equation and its impact on prognosis in a predominantly White European population	20
Young adults have worse kidney transplant outcomes than other age groups	20
Metabolic dysfunction–associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease	20
Assisted peritoneal dialysis and transfer to haemodialysis: a cause-specific analysis with data from the RDPLF	20
Dynapaenia and sarcopaenia in chronic haemodialysis patients: do muscle weakness and atrophy similarly influence poor outcome?	20
Renal transplant outcomes in amyloidosis	20
Climate change and nephrology	20
Increasing incidence and improved survival in ANCA-associated vasculitis—a Danish nationwide study	19
Muscle protein turnover and low-protein diets in patients with chronic kidney disease	19
Urinary excretion of epidermal growth factor and rapid loss of kidney function	19
The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation	19
Fibrosis and cancer: shared features and mechanisms suggest common targeted therapeutic approaches	18
Armed conflicts and kidney patients: a consensus statement from the Renal Disaster Relief Task Force of the ERA	18
Factors associated with sex differences in the risk of kidney stones	18
Hydroxychloroquine and azithromycin tolerance in haemodialysis patients during COVID-19 infection	18
The ‘other’ big complication: how chronic kidney disease impacts on cancer risks and outcomes	18
Renal denervation: where do we stand and what is the relevance to the nephrologist?	18
Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis	18
Patient-reported factors influencing the choice of their kidney replacement treatment modality	18
Lactobacillus rhamnosus L34 attenuates chronic kidney disease progression in a 5/6 nephrectomy mouse model through the excretion of anti-inflammatory molecules	18
Circulating plasmablasts and high level of BAFF are hallmarks of minimal change nephrotic syndrome in adults	18
LB002ILLUMINATE-A, A PHASE 3 STUDY OF LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC, IN CHILDREN AND ADULTS WITH PRIMARY HYPEROXALURIA TYPE 1 (PH1)	18
Serum biomarkers of iron stores are associated with worse physical health-related quality of life in nondialysis-dependent chronic kidney disease patients with or without anemia	18
Sodium zirconium cyclosilicate increases serum bicarbonate concentrations among patients with hyperkalaemia: exploratory analyses from three randomized, multi-dose, placebo-controlled trials	18
Interim analysis of the COSA (COVID-19 patients treated with the Seraph® 100 Microbind® Affinity filter) registry	18
The efficacy and safety of roxadustat for anemia in patients with chronic kidney disease: a meta-analysis	17
COVID-19 outbreak in vaccinated patients from a haemodialysis unit: antibody titres as a marker of protection from infection	17
Voclosporin: a novel calcineurin inhibitor with no impact on mycophenolic acid levels in patients with SLE	17
COVID-19 vaccination in haemodialysis patients: good things come in threes…	17
Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials	17
Tubular phosphate handling: references from child to adulthood in the era of standardized serum creatinine	17
Precision medicine approaches for diabetic kidney disease: opportunities and challenges	17
Protein carbamylation and chronic kidney disease progression in the Chronic Renal Insufficiency Cohort Study	17
Distal renal tubular acidosis: ERKNet/ESPN clinical practice points	17
Causal effects of physical activity or sedentary behaviors on kidney function: an integrated population-scale observational analysis and Mendelian randomization study	17
Renal function decline in older men and women with advanced chronic kidney disease—results from the EQUAL study	17
Water intake and progression of chronic kidney disease: the CKD-REIN cohort study	17
The consequences of altered microbiota in immune-related chronic kidney disease	16
Heart failure in chronic kidney disease: the emerging role of myocardial fibrosis	16
Lifelong effect of therapy in young patients with the COL4A5 Alport missense variant p.(Gly624Asp): a prospective cohort study	16
Pre-eclampsia is a valuable opportunity to diagnose chronic kidney disease: a multicentre study	16
Risk factors for venous thromboembolism in patients with nephrotic syndrome: a retrospective cohort study	16
Does kidney transplantation with a standard or expanded criteria donor improve patient survival? Results from a Belgian cohort	15
Blood pressure monitoring in kidney transplantation: a systematic review on hypertension and target organ damage	15
Serum hemoglobin concentration and risk of renal function decline in early stages of diabetic kidney disease: a nationwide, biopsy-based cohort study	15
Acidosis, cognitive dysfunction and motor impairments in patients with kidney disease	15
Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study	15
Phosphoinositide 3-kinase γ deficiency attenuates kidney injury and fibrosis in angiotensin II–induced hypertension	15
The clinical characteristics of coronavirus-associated nephropathy	15
Long-term outcomes of COVID-19 survivors with hospital AKI: association with time to recovery from AKI	15
Peripheral neuropathy: an important contributor to physical limitation and morbidity in stages 3 and 4 chronic kidney disease	15
Humoral response after the fourth dose of the SARS-CoV-2 vaccine in the CKD spectrum: a prespecified analysis of the SENCOVAC study	15
Precision medicine in Fabry disease	15
Efficacy and safety of combination therapy with sodium–glucose cotransporter 2 inhibitors and renin–angiotensin system blockers in patients with type 2 diabetes: a systematic review and meta-analysis	15
The Prepare for Kidney Care Study: prepare for renal dialysis versus responsive management in advanced chronic kidney disease	15
Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study	14

Chronic kidney disease, physical activity and cognitive function in older adults—results from the National Health and Nutrition Examination Survey (2011–2014)	14
Outcome and effect of vaccination in SARS-CoV-2 Omicron infection in hemodialysis patients: a cohort study	14
Systematic review of the nuclear factor erythroid 2-related factor 2 (NRF2) system in human chronic kidney disease: alterations, interventions and relation to morbidity	14
Regenerating tubular epithelial cells of the kidney	14
Pre-kidney transplant unintentional weight loss leads to worse post-kidney transplant outcomes	14
β-blocker dialyzability and the risk of mortality and cardiovascular events in patients undergoing hemodialysis	14
Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors	14
Association of urinary sex steroid hormones with urinary calcium, oxalate and citrate excretion in kidney stone formers	14
International peritoneal dialysis training practices and the risk of peritonitis	14
Routine serum biomarkers, but not dual-energy X-ray absorptiometry, correlate with cortical bone mineral density in children and young adults with chronic kidney disease	14
The receptor activator of nuclear factor κΒ ligand receptor leucine-rich repeat-containing G-protein-coupled receptor 4 contributes to parathyroid hormone-induced vascular calcification	14
LB004A RANDOMIZED, CONTROLLED TRIAL OF RITUXIMAB VERSUS AZATHIOPRINE AFTER INDUCTION OF REMISSION WITH RITUXIMAB FOR PATIENTS WITH ANCA-ASSOCIATED VASCULITIS AND RELAPSING DISEASE	14
Albuminuria as a risk factor for mild cognitive impairment and dementia—what is the evidence?	14
DNA methylation profiling identifies epigenetic differences between early versus late stages of diabetic chronic kidney disease	13
Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment	13
Dietary magnesium supplementation inhibits abdominal vascular calcification in an experimental animal model of chronic kidney disease	13
Clinical events and patient-reported outcome measures during CKD progression: findings from the Chronic Renal Insufficiency Cohort Study	13
Decreased kidney function and agricultural work: a cross-sectional study in middle-aged adults from Tierra Blanca, Mexico	13
CONVINCE in the context of existing evidence on haemodiafiltration	13
Long-term risks after kidney donation: how do we inform potential donors? A survey from DESCARTES and EKITA transplantation working groups	13
Itching in dialysis patients: impact on health-related quality of life and interactions with sleep problems and psychological symptoms—results from the RENINE/PROMs registry	13
Effect of fructooligosaccharide on endothelial function in CKD patients: a randomized controlled trial	13
Pilot study of reloxaliase in patients with severe enteric hyperoxaluria and hyperoxalemia	13
Factors influencing fertility rates in Australian women receiving kidney replacement therapy: analysis of linked Australia and New Zealand Dialysis and Transplant Registry and perinatal data over 22 y	13
Humoral response after SARS-CoV-2 vaccination in patients undergoing maintenance haemodialysis: loss of immunity, third dose and non-responders	13
Survival of patients who opt for dialysis versus conservative care: a systematic review and meta-analysis	13
Loss of humoral response 3 months after SARS-CoV-2 vaccination in the CKD spectrum: the multicentric SENCOVAC study	13
Evidence of an intestinal phosphate transporter alternative to type IIb sodium-dependent phosphate transporter in rats with chronic kidney disease	13
Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients: seroconversion and presence of neutralizing antibodies	12
Mechanisms of myostatin and activin A accumulation in chronic kidney disease	12
RESET-PKD: a pilot trial on short-term ketogenic interventions in autosomal dominant polycystic kidney disease	12
Regression of diabetic nephropathy by treatment with empagliflozin in BTBR ob/ob mice	12
Sex difference in ambulatory blood pressure control associates with risk of ESKD and death in CKD patients receiving stable nephrology care	12
MO039THE 24-WEEK INTERIM ANALYSIS RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY OF ATACICEPT IN PATIENTS WITH IGA NEPHROPATHY AND PERSISTENT PROTEINURIA	12
Long-term outcome of the survivors of infantile hypercalcaemia with CYP24A1 and SLC34A1 mutations	12
Long-term renal survival of paediatric patients with lupus nephritis	12
Time-dependent evolution of IgG antibody levels after first and second dose of mRNA-based SARS-CoV-2 vaccination in haemodialysis patients: a multicentre study	12
Prolonged patient survival after implementation of a continuous quality improvement programme empowered by digital transformation in a large dialysis network	12
Association of osteopontin with kidney function and kidney failure in chronic kidney disease patients: the GCKD study	12
Lessons learned during the war in Ukraine: a report from the Renal Disaster Relief Task Force of the ERA	12
Identification of a serum and urine extracellular vesicle signature predicting renal outcome after kidney transplant	12
Types of erythropoiesis-stimulating agents and risk of end-stage kidney disease and death in patients with non-dialysis chronic kidney disease	12
Complement inhibitors for kidney disease	12
Prognostic models for chronic kidney disease: a systematic review and external validation	12
Patient- and parent proxy-reported outcome measures for life participation in children with chronic kidney disease: a systematic review	12
The reasons for a clinical trial on incremental haemodialysis	12
Laxative use in patients with advanced chronic kidney disease transitioning to dialysis	12
Association between thrombotic microangiopathy and activated alternative complement pathway in malignant nephrosclerosis	12
Can the assessment of ultrasound lung water in haemodialysis patients be simplified?	12
Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis	12
Physical activity and risk of cardiovascular events and all-cause mortality among kidney transplant recipients	12
Immunoglobulin A nephropathy in association with inflammatory bowel diseases: results from a national study and systematic literature review	11
Sequential rituximab therapy sustains remission of nephrotic syndrome but carries high risk of adverse effects	11
Induction and maintenance of remission with mycophenolate mofetil in ANCA-associated vasculitis: a systematic review and meta-analysis	11
Drug prescription in patients with chronic kidney disease: a true challenge	11
Clinical and genetic spectra of autosomal dominant tubulointerstitial kidney disease	11
Inflammation and physical dysfunction: responses to moderate intensity exercise in chronic kidney disease	11
Chronic hypoxia exacerbates diabetic glomerulosclerosis through mesangiolysis and podocyte injury in db/db mice	11
Effects of the chymase inhibitor fulacimstat in diabetic kidney disease—results from the CADA DIA trial	11
Patterns of renal osteodystrophy 1 year after kidney transplantation	11
C3 glomerulopathy associated with monoclonal gammopathy: impact of chronic histologic lesions and beneficial effects of clone-targeted therapies	11
Screening of Fabry disease in patients with chronic kidney disease in Japan	11
An intradialytic non-immersive virtual reality exercise programme: a crossover randomized controlled trial	11
Semiquantitative assessed proteinuria and risk of heart failure: analysis of a nationwide epidemiological database	11
Weekly seroconversion rate of the mRNA-1273 SARS-CoV-2 vaccine in haemodialysis patients	11
The kidney reabsorption-related magnesium depletion score is associated with increased likelihood of abdominal aortic calcification among US adults	11
Recommendations for the management of patients with immune-mediated kidney disease during the severe acute respiratory syndrome coronavirus 2 pandemic	11
Using a generic definition of cachexia in patients with kidney disease receiving haemodialysis: a longitudinal (pilot) study	11
Results of the European EDITH nephrologist survey on factors influencing treatment modality choice for end-stage kidney disease	11
Impact of different COVID-19 waves on kidney replacement therapy epidemiology and mortality: REMER 2020	11
Immune checkpoint inhibitor–associated hypercalcaemia	11
Novel in vitro assays to detect circulating permeability factor(s) in idiopathic focal segmental glomerulosclerosis	11
mRNA-1273 vaccine (Moderna): a better option than BNT162b2 (Pfizer) in kidney transplant recipients and dialysis patients?	11
The incidence and prevalence of IgA nephropathy in Europe	11
Overcoming barriers in the design and implementation of clinical trials for acute kidney injury: a report from the 2020 Kidney Disease Clinical Trialists meeting	11
Identifying key predictors of mortality in young patients on chronic haemodialysis—a machine learning approach	10
Association of single and serial measures of serum phosphorus with adverse outcomes in patients on peritoneal dialysis: results from the international PDOPPS	10
Combining phosphate binder therapy with vitamin K2 inhibits vascular calcification in an experimental animal model of kidney failure	10
Kidney transplantation in patients with multiple myeloma: narrative analysis and review of the last two decades	10
Don’t forget the zinc	10
Asystole episodes and bradycardia in patients with end-stage renal disease	10
Circulating angiopoietin-2 and angiogenic microRNAs associate with cerebral small vessel disease and cognitive decline in older patients reaching end-stage renal disease	10
Temporal trends in the quality of deceased donor kidneys and kidney transplant outcomes in Europe: an analysis by the ERA-EDTA Registry	10
Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib	10
Recent findings on the clinical utility of renal magnetic resonance imaging biomarkers	10
Longitudinal change in proteinuria and kidney outcomes in C3 glomerulopathy	10
Nephrology: achieving sustainability	10
Barriers to conservative care from patients’ and nephrologists’ perspectives: the CKD-REIN study	10
Serum levels of IL-6, IL-8 and IL-10 and risks of end-stage kidney disease and mortality	10
Treatment of secondary hyperparathyroidism in non-dialysis CKD: an appraisal 2022s	10
Perspectives on mental health among patients receiving dialysis	10
COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab	10
IgA nephropathy in adults—treatment standard	10
Adding creatinine to routine pregnancy tests: a decision tree for calculating the cost of identifying patients with CKD in pregnancy	10
Determining the optimal cholecalciferol dosing regimen in children with CKD: a randomized controlled trial	10